Is Boston Scientific (BSX) Becoming the Leading MedTech Growth Story?

Boston Scientific Corp. (NYSE:BSX) is one of the best stocks to buy according to Citadel LLC. On October 22, Josh Jennings, an analyst at TD Cowen, reiterated his $115 price target and Buy rating on the stock after the company reported strong Q3 2025 results.

Jennings said the company’s 15.3% organic growth was the highlight of the quarterly results and came ahead of the company’s guidance. The robust organic growth was driven by strong performance in the Electrophysiology and Watchman businesses within the Cardiology segment. This growth not only helped the company report stronger sales and EPS but also enabled it to outperform street expectations.

Copyright: nimon / 123RF Stock Photo

The analyst was also impressed by the guidance, as the company expects both growth and profitability to improve, and has raised it for the third time this year. For 2025, the company expects organic sales to grow by around 20% on a reported basis and 15.5% on an organic basis. This was a rise over the earlier guide of 18%-19% and 14%-15%, respectively. Jennings also highlighted the company’s positive outlook on margins, which supported his bullish stance.

Boston Scientific Corp. (NYSE:BSX) is a global medical technology company that develops, manufactures, and markets a wide range of medical devices. Its portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, oncological, neurological, and urological diseases and conditions.

While we acknowledge the risk and potential of BSX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BSX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Goldman Sachs Defense Stocks: Top 10 Stocks to Buy and  13 Best Tech Stocks Under $10 to Invest In.

Disclosure: None. This article is originally published at Insider Monkey.